See more : Heart Test Laboratories, Inc. (HSCSW) Income Statement Analysis – Financial Results
Complete financial analysis of PMV Pharmaceuticals, Inc. (PMVP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PMV Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- West Leisure Resorts Limited (WESTLEIRES.BO) Income Statement Analysis – Financial Results
- Sime Darby Plantation Berhad (SDPNF) Income Statement Analysis – Financial Results
- Kyoto Group AS (KYOTO.OL) Income Statement Analysis – Financial Results
- Eastern Platinum Limited (ELR.TO) Income Statement Analysis – Financial Results
- LATAM Airlines Group S.A. (LTM) Income Statement Analysis – Financial Results
PMV Pharmaceuticals, Inc. (PMVP)
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| Gross Profit | -1.26M | -650.00K | -1.28M | -318.00K | -388.00K | -338.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.89M | 51.99M | 36.49M | 23.93M | 20.76M | 13.85M |
| General & Administrative | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Other Expenses | 0.00 | 87.00K | 21.00K | -143.00K | -8.00K | 16.00K |
| Operating Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Cost & Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Interest Income | 11.17M | 3.63M | 449.00K | 651.00K | 1.30M | 1.34M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| EBITDA | -78.88M | -76.73M | -57.99M | -34.62M | -26.25M | -18.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.13M | -77.04M | -58.29M | -34.94M | -26.64M | -18.89M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.17M | 3.71M | 470.00K | 508.00K | 1.29M | 1.36M |
| Income Before Tax | -68.96M | -73.33M | -57.82M | -34.43M | -25.34M | -17.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | -9.00K | 23.00K | 6.00K | 8.00K | 3.00K |
| Net Income | -68.96M | -73.32M | -57.85M | -34.44M | -25.35M | -17.54M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| EPS Diluted | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| Weighted Avg Shares Out | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
| Weighted Avg Shares Out (Dil) | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
Top 10 most-shorted stocks as of November 2022
The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with...
PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know
PMV Pharmaceuticals, Inc. (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President &...
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion...
PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief...
PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CRANBURY, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief...
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies designed to target p53 mutants, today reported financial results for the second quarter...
PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief...
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the quarter ended March 31,...
Source: https://incomestatements.info
Category: Stock Reports